CDK4/6 inhibitors in advanced HR+/HER2- breast cancer – a multicenter real world data analysis

Conclusion: Our RWD analysis on CDK4/6i treatment in Germa ny supports data from RCTs regarding both treatment efficacy and safety of CDK4/6i for treatment of patients with HR+/HER2- ABC. In comparison to data from the pivotal RCTs, median PFS was lower but within the expected range for RWD which could result from inclusion of patients with more advanced di sease (i.e., higher therapy lines) to our dataset.
Source: Breast Care - Category: Cancer & Oncology Source Type: research